Current perspectives on rosuvastatin
Miao Hu, Brian Tomlinson Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin, Hong Kong Abstract: Rosuvastatin is one of the most potent statins available for reducing circulating low-density lipoprotein cholesterol (LDL-C) levels, which enables more high-risk patients t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-04-01
|
| Series: | Integrated Blood Pressure Control |
| Online Access: | http://www.dovepress.com/current-perspectives-on-rosuvastatin-a12803 |
| _version_ | 1811205208913477632 |
|---|---|
| author | Hu M Tomlinson B |
| author_facet | Hu M Tomlinson B |
| author_sort | Hu M |
| collection | DOAJ |
| description | Miao Hu, Brian Tomlinson Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin, Hong Kong Abstract: Rosuvastatin is one of the most potent statins available for reducing circulating low-density lipoprotein cholesterol (LDL-C) levels, which enables more high-risk patients to achieve their lipid goals. Its favorable balance of effects on atherogenic and protective lipoproteins and its pleiotropic effects, including anti-inflammatory and antioxidant effects and improvement in endothelial dysfunction, are associated with slowing of progression of atherosclerosis within the artery wall and have been translated into clinical benefits for cardiovascular outcomes. This review provides an update on the safety and the efficacy of rosuvastatin in recent large clinical trials. It appears that rosuvastatin has a beneficial effect on the progression of atherosclerosis across the clinical dosage range of 2.5–40 mg. It reduced cardiovascular events in relatively low-risk subjects with elevated high-sensitivity C-reactive protein and normal low-density lipoprotein cholesterol. As with other statins, rosuvastatin did not show overall benefit in terms of survival in patients with heart failure, but certain clinical or biochemical markers reflecting underlying disease characteristics may help to identify subgroups of patients that benefit from statin therapy. In patients with end-stage renal disease undergoing chronic hemodialysis, rosuvastatin had no effect on reducing cardiovascular events. Although there is a slightly increased risk of incident diabetes with this class of agents, the absolute benefits of statin therapy on cardiovascular events overweigh the risk in patients with moderate or high cardiovascular risk or with documented cardiovascular disease. As with other statins, rosuvastatin is an appropriate therapy in addition to antihypertensive treatment to reduce cardiovascular risk in hypertensive patients. Keywords: atherosclerosis, cardiovascular disease, lipids, rosuvastatin |
| first_indexed | 2024-04-12T03:26:53Z |
| format | Article |
| id | doaj.art-25decd71aba64cbda7f4117cdfb3cf89 |
| institution | Directory Open Access Journal |
| issn | 1178-7104 |
| language | English |
| last_indexed | 2024-04-12T03:26:53Z |
| publishDate | 2013-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Integrated Blood Pressure Control |
| spelling | doaj.art-25decd71aba64cbda7f4117cdfb3cf892022-12-22T03:49:39ZengDove Medical PressIntegrated Blood Pressure Control1178-71042013-04-012013default1525Current perspectives on rosuvastatinHu MTomlinson BMiao Hu, Brian Tomlinson Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin, Hong Kong Abstract: Rosuvastatin is one of the most potent statins available for reducing circulating low-density lipoprotein cholesterol (LDL-C) levels, which enables more high-risk patients to achieve their lipid goals. Its favorable balance of effects on atherogenic and protective lipoproteins and its pleiotropic effects, including anti-inflammatory and antioxidant effects and improvement in endothelial dysfunction, are associated with slowing of progression of atherosclerosis within the artery wall and have been translated into clinical benefits for cardiovascular outcomes. This review provides an update on the safety and the efficacy of rosuvastatin in recent large clinical trials. It appears that rosuvastatin has a beneficial effect on the progression of atherosclerosis across the clinical dosage range of 2.5–40 mg. It reduced cardiovascular events in relatively low-risk subjects with elevated high-sensitivity C-reactive protein and normal low-density lipoprotein cholesterol. As with other statins, rosuvastatin did not show overall benefit in terms of survival in patients with heart failure, but certain clinical or biochemical markers reflecting underlying disease characteristics may help to identify subgroups of patients that benefit from statin therapy. In patients with end-stage renal disease undergoing chronic hemodialysis, rosuvastatin had no effect on reducing cardiovascular events. Although there is a slightly increased risk of incident diabetes with this class of agents, the absolute benefits of statin therapy on cardiovascular events overweigh the risk in patients with moderate or high cardiovascular risk or with documented cardiovascular disease. As with other statins, rosuvastatin is an appropriate therapy in addition to antihypertensive treatment to reduce cardiovascular risk in hypertensive patients. Keywords: atherosclerosis, cardiovascular disease, lipids, rosuvastatinhttp://www.dovepress.com/current-perspectives-on-rosuvastatin-a12803 |
| spellingShingle | Hu M Tomlinson B Current perspectives on rosuvastatin Integrated Blood Pressure Control |
| title | Current perspectives on rosuvastatin |
| title_full | Current perspectives on rosuvastatin |
| title_fullStr | Current perspectives on rosuvastatin |
| title_full_unstemmed | Current perspectives on rosuvastatin |
| title_short | Current perspectives on rosuvastatin |
| title_sort | current perspectives on rosuvastatin |
| url | http://www.dovepress.com/current-perspectives-on-rosuvastatin-a12803 |
| work_keys_str_mv | AT hum currentperspectivesonrosuvastatin AT tomlinsonb currentperspectivesonrosuvastatin |